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Aims Several high-sensitivity cardiac troponin (hs-cTn) assays have recently been developed. It is unknown which hs-cTn pro-
vides the most accurate prognostic information and to what extent early changes in hs-cTn predict mortality.
Methods
and results
In a prospective, international multicentre study, cTn was simultaneously measured with three novel [high-sensitivity
cardiac Troponin T (hs-cTnT), Roche Diagnostics; hs-cTnI, Beckman-Coulter; hs-cTnI, Siemens] and a conventional
assay (cTnT, Roche Diagnostics) in a blinded fashion in 1117 unselected patients with acute chest pain. Patients were fol-
lowed up 2 years regarding mortality. Eighty-two (7.3%) patients died during the follow-up. The 2-year prognostic accur-
acy of hs-cTn was most accurate for hs-cTnT [area under the receivers operating characteristic curve (AUC) 0.78 (95%
CI: 0.73–0.83) and outperformed both hs-cTnI (Beckman-Coulter, 0.71 (95% CI: 0.65–0.77; P ¼ 0.001 for comparison),
hs-cTnI (Siemens) 0.70 (95% CI: 0.64–0.76; P, 0.001 for comparison)] and cTnT 0.67 (95% CI: 0.61–0.74; P, 0.001 for
comparison). Absolute changes of hs-cTnT were more accurate than relative changes in predicting mortality, but inferior
to presentation values of hs-cTnT. Combining changes of hs-cTnT within the first 6 h with their presentation values did
not further improve prognostic accuracy. Similar results were obtained for both hs-cTnI assays regarding the incremental
value of changes. Hs-cTn concentrations remained predictors of death in clinically challenging subgroups such as patients
with pre-existing coronary artery disease, impaired renal function, and patients older than 75 years.
Conclusion High-sensitivity cardiac Troponin T is more accurate than hs-cTnI in the prediction of long-term mortality. Changes of
hs-cTn do not seem to further improve risk stratification beyond initial presentation values.
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Introduction
Identifying acute chest pain patients at high risk for death remains a
clinical challenge. Cardiac troponin is the preferred cardiac biomark-
er quantifying cardiomyocyte damage for diagnosis and risk assess-
ment in patients presenting with suspected acute myocardial
infarction (AMI).1 The early diagnosis of AMI has been markedly
improved by the introduction of novel high-sensitivity cardiacTropo-
nin (hs-cTn) assays in comparison with prior generation assays.2,3
Rise and fall of cTn is a prerequisite for the diagnosis of AMI.4 Recent-
ly, absolute (vs. relative) changes in the diagnosis of AMI have been
shown to further improve diagnostic accuracy.5,6
Numerous studies have demonstrated a strong independent rela-
tionship between cTn and prognosis.7 Novel hs-cTn assays are able
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to measure around the 99th percentile with high precision. This has
led to an increase in the numberof patients detected to have mild ele-
vations in hs-cTn. Many of these patients are finally found to have
cardiac disorders other than AMI. Frequently, clinicians are unsure
about the prognostic clinical relevance of low elevations of hs-cTn
and quantifiable values below the 99th percentile and are inclined
to ascribe (minor) elevations of hs-cTn values to a patient’s advanced
age, impaired renal function, or pre-existing coronary artery disease.
In contrast to diagnostic considerations, the relevance of early
changes of hs-cTn for prognosis is unknown.
We performed a large prospective, observational, international,
multicentre study to examine the prognostic performance of novel
biomarkers in unselected patients presenting to the emergency de-
partment (ED) with acute chest pain. In this analysis, we scrutinized
the early and long-term prognostic accuracy of three novel hs-cTn
assays in comparison with a conventional cTn assay. We studied
the incremental value of early changes of hs-cTn for prognosis and
evaluated the prognostic accuracy of hs-cTn assays in important sub-
groups.
Methods
Study design and population
Advantageous Predictors of Acute Coronary Syndrome Evaluation
(APACE) is an ongoing prospective international multicentre study
designed and coordinated by the University Hospital Basel, Switzerland.
From April 2006 to June 2009, a total of 1267 consecutive patients pre-
senting to the ED with symptoms suggestive of AMI of ,12 h were en-
rolled.3 To reach a high rate of comparability, patients were included if
simultaneous measurements of three hs-cTn assays [high-sensitivity
cardiac Troponin T (hs-cTnT), Roche Diagnostics; hs-cTnI, Beckman-
Coulter; and hs-cTnI Siemens] and conventional cTnT (Roche Diagnos-
tics) were performed at presentation and serially thereafter, yielding to a
study population of 1117 patients (Figure 1). Baseline characteristics did
not differ significantly between patients included and those not consid-
ered for the respective analyses. There were no technical errors with
any of the assays studied. The majority of patients were enrolled by the
University Hospital of Basel, Switzerland (74.9%), followed by Hospital
del Mar, Barcelona, Spain (13.2%), Hospital of Limmattal, Switzerland
(7.2%), Cantonal Hospital of Olten, Switzerland (4.7%). Patients with ter-
minal kidney failure requiring dialysis were excluded. The study was
carried out according to the principles of the Declaration of Helsinki
and approved by the local ethics committees at each institution.
Written informed consent was obtained from all patients. The authors
designed the study, gathered and analysed the data, vouch for the data
and analysis, wrote the paper, and decided to publish. The sponsors
had no role in conducting the study or analysing the data.
Routine clinical assessment
All the patients underwent an initial clinical assessment that included
clinical history, physical examination, 12-lead ECG, continuous ECG-
monitoring, pulse oximetry, standard blood tests and chest radiography.
Cardiac troponin, the MB fraction of creatine kinase and myoglobin were
measured at presentation and after 6–9 h as long as clinically indicated.
Treatment of patients was left to the discretion of the attending physi-
cians who were unaware of the centrally measured hs-cTn values and
only aware of the locally available conventional troponin results. All
12-lead ECGs were assessed as recommended in current guidelines4 in
a core lab by internal medicine specialists blinded to patient details.
Adjudicated final diagnosis
Adjudication of final diagnoses was performed centrally in the core lab
(University Hospital Basel) for all patients twice: Once according to con-
ventional cTn levels used onsite (this method was used in the initial ana-
lyses to examine the performance of hs-cTn assays8–12) and once
including levels of Roche hs-cTnT in order to also take advantage of
the higher sensitivity and higher overall diagnostic accuracy offered by
hs-cTn assays6 (this allows the additional detection of small AMIs that
were missed by the adjudication based on conventional cTn assays).
Two independent cardiologists reviewed all available medical records—
patient history, physical examination, results of laboratory testing
(including hs-cTnT levels), radiologic testing, ECG, echocardiography,
cardiac exercise test, lesion severity, and morphology in coronary
angiography—pertaining to the patient from the time of ED presentation
to 90-day follow-up. In situations of disagreement about the dia-
gnosis, cases were reviewed and adjudicated in conjunction with a third
cardiologist.
Acute myocardial infarction was defined and cTn levels interpreted as
recommended in current guidelines.13,14 In brief, AMI was diagnosed
when there was evidence of myocardial necrosis in association with a
Figure 1 Flow diagram displaying the proportions of patients with troponin measurements available from all eligible patients and the resulting
study population with simultaneously all four troponin measurements available.
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clinical setting consistent with myocardial ischaemia. Myocardial necrosis
was diagnosed by at least one cTn value above the 99th percentile (or for
the conventional cTn assays above the 10% imprecision value if not ful-
filled at the 99th percentile) together with a significant rising and/or
falling.11,14,15 The criteria used to define rise and/or fall in conventional
cTn and hs-cTnT are described in detail in Supplementary material
online, Method.
Unstable angina was diagnosed in patients with normal cardiac tropo-
nin levels and typical angina at rest, a deterioration of a previously stable
angina and in casesof positive cardiacexercise testing orcardiac catheter-
ization with coronary arteries found to have a stenosis of 70% or greater.
As we adjudicated the cause of the presentation to the ED (¼acute chest
pain) and not the cause of elevations of hs-cTnT, ‘stable coronary artery
disease (CAD)’ was not a diagnostic group: a patient with ‘stable CAD’
with acute myocardial ischaemia at rest (acute chest pain) would there-
fore be classified as either ‘unstable angina’ or ‘acute myocardial infarc-
tion’. A further category was non-cardiac chest pain (such as
musculoskeletal pain, gastroesophageal disorder). If no sufficient conclu-
sive diagnostic procedures were performed, symptoms were classified as
to be of unknown origin.
Follow-up and clinical endpoints
Afterhospital dischargepatientswere followedafter3, 12, and 24months
by telephone or inwritten form.Any clinical (cardiovascular) events since
presentation to the ED were collected by establishing contact with the
patient and his family physician. Information regarding death was also
obtained from the national registry on mortality. The primary endpoint
was all-cause mortality.
Investigational high-sensitivity cardiac
troponin analysis
Blood samples for determination of hs-cTn were collected at presenta-
tion to the ED and serially thereafter at 1, 2, 3, and 6 h. Serial sampling
was discontinued when the diagnosis of AMI was certain and treatment
required transferring the patient to the catheter laboratory. All four
troponin samples were frozen at 2808C until assayed in a blinded
fashion in a dedicated core laboratory. High-sensitivity cardiac Troponin
T was measured on the Elecsys 2010 (Roche Diagnostics), limit of blank
and limit of detection (LoD) have been determined to be 3 and 5 ng/L, an
imprecision corresponding to 10% coefficient of variation was reported
at 13 ng/L and the 99th percentile of a healthy reference population at
14 ng/L,12 cTnT (4th generation) was measured on the Elecsys 2010
(Roche Diagnostics); LoD of 0.01 mg/L, a 99th percentile cut-off value
of 0.01 mg/L and a coefficient of variation of ,10% at 0.035 mg/L.
Beckman-Coulter hs-cTnI was measured on the Access 2 analyser
using an investigational prototype assay. According to the manufacturer,
LoD is 2 ng/L, the 99th percentile of a healthy reference population is
9 ng/L with a 10% CV lower than the 99th percentile. For Siemens
hs-cTnI, LoD is 5 ng/L, the imprecision level corresponding to 10% CV
is found at 3 ng/L and the 99th percentile of a healthy reference popula-
tion is 9 ng/L (all data according to the manufacturer).
Statistical analysis
Comparisons between groups were made using the x2 method, Mann–
Whitney U, or Kruskal–Wallis test. Receivers operating characteristic
(ROC) curves were constructed to assess the sensitivity and specificity
of hs-cTn assays and compared as recommended by DeLong et al.16
For the ROC analysis for 730-day mortality, patients who were alive at
last patient contact and who had an observation time of slightly ,730
days were not excluded but counted as survivors (as this was the latest
information available). Optimal cut-offs of ROC curve analysis were
chosen by scrutinizing Youden indices. Correlations between continuous
variables were assessed using the Spearman rank-correlation method.
For comparisons of nested models likelihood-ratios were used. The
Kaplan–Meier method was employed to analyse the timing of events
during the follow-up. Statistical assessment was performed using the
log-rank test.
Patients were categorized in three groups both below and above the
99th percentile of each respective troponin assay. This was done by
both minimizing differences in the size of groups of one hs-cTn assay
and to reach comparable group sizes for all hs-cTn assays. Besides,
patients were also categorized in equally large hexiles.
Maximum, numerical, absolute changes were calculated for all patients
within the first 6 h after presentation compared with the first value at
presentation (0 h value). All serial measurements available (see also Sup-
plementary material online, Table S1) were used for this calculation for
each patient. The percentage change between the 0 h value of hs-cTnT
and the respective 1h-value was calculated and the numerical change
used for all calculations and illustrations.
All hypothesis testing was two-tailed and a P-value of ,0.05 was
considered statistically significant. All statistical analyses were performed
using SPSS for Windows 19.0 (IBM) and MedCalc 9.6.4.0 (MedCalc
Software).
Results
Characteristics of patients
Baseline characteristicsof the 1117 patients are shown inTable 1. The
adjudicated final diagnosis was AMI in 215 (19.2%) patients (21%
STEMI, 79% NSTEMI), unstable angina in 11.3%, cardiac symptoms
of origin other than coronary artery disease in 14.0%, non-cardiac
symptoms in 46.3%, and symptoms of unknown origin in 9.2%. All
the patients were followed up with a median follow-up time of 798
days (IQR: 738–926). Ninety-two patients (8%) who did not die
during follow-up had a follow-up period shorter than 730 days
[median follow-up of 483 days (IQR: 399–631) in this patient
group] (Supplementary material online, Table S2). Since APACE is
an on-going study, 730 days of follow-up are not yet available in all
patients enrolled in the study.
Levels of high-sensitivity cardiac troponin
in survivors and non-survivors
Levels of hs-cTn for patients who died within 30 days, respectively,
730 days in comparison with survivors are displayed in Figure 2A
and B and Supplementary material online, Figure S1A and B. There
was no significant difference in hs-cTnT concentrations of patients
with STEMI [median 116 ng/L (IQR 26–579 ng/L)] and patients
with NSTEMI [median 80 ng/L (IQR: 30–196 ng/L)] (P ¼ 0.254 for
comparison). The median time to presentation did not differ signifi-
cantly between patients with STEMI and NSTEMI.
High-sensitivity cardiac Troponin T had a moderately high correl-
ation with hs-cTnI (Beckman-Coulter) (0.769) and hs-cTnI (Siemens)
(0.758), and a low correlation with cTnT (0.376). The correlation
between both hs-cTnI assays amounted to 0.785. When the analysis
was carried out in groups according to the final diagnosis of AMI, dif-
ferent resultswereobserved: inter-assay correlations in the non-AMI
group were much lower than in all patients and assays of patients with
AMI at presentation displayed very high correlation numbers, with
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near-perfect correlation between the two cTnT assays (Supplemen-
tary material online, Figure S2).
Prognostic accuracy of high-sensitivity
cardiac troponin
During a follow-up time of 730 days 82 patients (7.3%) died with a
median time to death of 189 days (IQR: 40–473). Of the 82 patients
who died within the first 730 days, 31 patients (38%) suffered from
cardiac death, 13 patients (16%) pulmonic death, 8 patients (10%)
had other causes of death, and 30 patients (37%) unknown cause of
death. Forty patients with AMI (18.6%) and 42 patients without
AMI (4.7%) died during the first 730 days of follow-up.
The diagnostic accuracy did not differ significantly between the
three hs-cTn assays, and only hs-cTnT outperformed the conven-
tional cTnT in the first 30 days (Table 2). No patient with an
hs-cTnT level ,9 ng/L died in the first 30 days. Both hs-cTnI assays
did not differ significantly from the AUC of cTnT (AUC: 0.76; 95%
CI: 0.64–0.89) (Figure 3A).
Long-term mortality (730 days) was most accurately predicted by
hs-cTnT (Roche Diagnostics) expressed by an AUC of 0.78 (95% CI:
0.73–0.83), sensitivity of 70.7%, specificity of 74.8%, negative predictive
value (NPV)97.0%, and PPV of 18.2%. Both hs-cTnI assays did not differ
significantly fromtheAUCofcTnT(AUC:0.67; 95%CI: 0.61–0.74) and
were inferior to hs-cTnT (Figure 3B). The risk of patients with negative
cTnT values, but elevated hs-cTn values at presentation is displayed in
Figure 3C. Fifty-four patients in this analysis had normal (i.e. below the
99th percentile) inaugural hs-cTnT values and simultaneously con-
verted to an elevated (.99th percentile) value in the first 6 h there-
after. Of these 54 patients, only 2 patients (4%) died during the first
730 days. There were no statistically significant differences for any of
the investigated assays between the centres providing internal valid-
ation of our results.
The prognostic accuracy for the prediction of myocardial infarc-
tion during the first 30 days of follow-up was not significant for any
of the fourassays; the AUCfor theprediction ofmyocardial infarction
in the first 730 days during the follow-up amounted to 0.64 (95% CI:
0.57–0.71) for both hs-cTnT and hs-cTnI (Beckman-Coulter); AUC
of 0.63 (95% CI: 0.56–0.70) for hs-cTnI (Siemens), and an AUC of
0.58 (95% CI: 0.50–0.66) for cTnT; P-values for comparison were
not significant between all four assays (Table 2).
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Table 1 Baseline characteristics of the patients
Characteristics All patients
(n5 1117)
Non-Survivors (2 year)
(n 5 82)
Survivors (2 year)
(n5 1035)
Age, year 64 (51–75) 80 (73–86) 62 (50–74)
Male gender, n (%) 743 (67) 59 (72) 684 (66)
Body mass indexa 26.4 (24.0–29.7) 25.4 (22.9–27.7) 26.5 (24.0–29.8)
Hypertension, n (%) 746 (67) 73 (89) 673 (65)
Hypercholesterolaemia, n (%) 497 (44) 43 (52) 454 (44)
Diabetes, n (%) 214 (19) 24 (29) 190 (18)
Current smoking, n (%) 271 (24) 13 (16) 258 (25)
History of smoking, n (%) 387 (35) 35 (43) 352 (34)
Pack years 30 (15–45) 40 (23–57) 30 (15–42)
Family history (18 grade) , n (%) 430 (38) 24 (29) 406 (39)
History, n (%)
Coronary artery disease 402 (36) 57 (70) 345 (33)
Previous myocardial infarction 273 (24) 43 (52) 230 (22)
Vital status
Heart rate, b.p.m. 76 (66–89) 83 (71–99) 75 (65–88)
Systolic blood pressure (mmHg) 142 (127–160) 131 (113–155) 143 (128–160)
Diastolic blood pressure (mmHg) 84 (74–93) 75 (67–88) 85 (75–93)
Glomerular filtration rate (mL/min/1.73 m2)b 89 (71–106) 65 (46–85) 90 (73–107)
Adjudicated final diagnosis, n (%)
STEMI 45 (4) 10 (12) 35 (3)
NSTEMI 170 (15) 30 (37) 140 (14)
Unstable angina 126 (11) 7 (9) 119 (11)
Cardiac, non-coronary disease 156 (14) 10 (12) 146 (14)
Non-cardiac symptoms 517 (46) 20 (24) 497 (48)
Unknown origin 103 (9) 5 (6) 98 (9)
aThe body mass index is the weight in kilograms divided by the square of the height in meters.
bGlomerular filtration rate was calculated using Modification of Diet in Renal Disease formula (MDRD).
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Intriguingly, in patients without AMI at presentation the prognostic
accuracy of hs-cTnT for the prediction of long-term mortality out-
performed all other assays significantly (Figure 3D); in patients with
AMI at presentation hs-cTnT and cTnT displayed the same high prog-
nostic accuracy, whereas both hs-cTnI assays did not even reach stat-
istical significance (Figure 3E). In patients with STEMI, neither any of
the four troponins studied (Table 4), nor TIMI flow (AUC: 0.59,
95% CI: 0.34–0.85, P ¼ 0.433), nor left-ventricular ejection fraction
(AUC: 0.69, 95% CI: 0.49–0.90, P-value 0.095) provided a significant
prognostic accuracy as to 730-day mortality.
The varying prognostic accuracy of all four troponin assays studied
stratified into the six main diagnostic groups is displayed in Table 4 for
730-day mortality and in Supplementary material online, Table S3 for
30-day mortality. The prognostic accuracy of all four troponin assays
studied as to the prediction of cardiac and non-cardiac mortality is
provided in Supplementary material online, Table S4. A gender-
specific prognostic analysis is provided in Supplementary material
online, Table S5.
Use of early and maximum changes
of high-sensitivity cardiac troponin
for the prediction of long-term
mortality (730 days)
Values of hs-cTnT have been determined serially within the first 6 h
after presentation at the ED (Figure 4; Supplementary material online,
Table S2 and Figure S3 and S4A–C). The prognostic accuracy of abso-
lute and relative changes of hs-cTnT in the first hour and maximum
changes in the first 6 h are displayed in Figure 5A. Absolute changes
outperformed relative changes in the accuracy of predicting long-
term mortality (730 days) but were inferior to presentation values.
Highest prognostic accuracy regarding changes of hs-cTnT was
achieved by the numerical absolute change in the first hour (|0–1 h
abs. change|) with an AUC of 0.66 (95% CI: 0.59–0.73) and by
|0–6 h abs. change| with an AUC of 0.69 (95% CI: 0.63–0.76).
Relative changes—both in the first h and in the first 6 h including
their respective numerical values (|value|) did not yield significant
AUC (Figure 5A).
The prognostic accuracy of the presentation value of hs-cTnT for
long-term mortality (AUC: 0.78; 95% CI: 0.73–0.83) could not be
improved by adding any changes of hs-cTnT within the first 6 h.
Using maximum values of hs-cTnT measured in the first 6 h yielded
to an AUC of 0.77 [95% CI: 0.72–0.82; P ¼ 0.051 for comparison
with presentation value (0 h value)] (Figure 5A).
Mortality rates for hs-cTnT values at presentation are displayed in
Figure 5B and Supplementary material online, Figure S5A and B for the
other troponin assays; mortality rates for maximum hs-cTnT values,
(numerical) absolute, and relative changes of hs-cTnT within the first
6 h are displayed in Supplementary material online, Figure S6.
Similar results were obtained when both hs-cTnI assays were
studied: neither changes nor maximum values of hs-cTnI occurring
in the first 6 h could outperform or further improve the prognostic
accuracy of their respective values at presentation (0 h value).
Prognostic accuracy of high-sensitivity
cardiac troponin in patients with
pre-existing coronary artery disease,
impaired renal function, and patients older
than 70 years
All three hs-cTn assays yielded significant AUC values for the predic-
tion of long-term mortality (730 days) in the three subgroups
(Table 3). Highest prognostic accuracy was achieved by hs-cTnT for
patients with pre-existing coronary artery disease (AUC: 0.74; 95%
CI: 0.67–0.81), and patients older than 70 years (AUC: 0.68; 95%
CI: 0.61–0.75) in comparison with both hs-cTnI assays. In patients
Figure 2 (A and B) Presentation values of high-sensitivity cardiac troponins and cardiac troponin T in survivors and non-survivors during the first
(A) 30 days and (B) 730 days; all values are displayed in nanogram per litre and as median values with inter-quartile ranges and outliers.
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Table 2 A prognostic performance of cardiac troponin assays during 2-year follow-up
n5 1117 AUC (95% CI) Optimal cut-off Sensitivity (%) specificity (%) NPV (%) PPV (%) hs-cTnI (BC) hs-cTnI (S) c-TnT (R4)
Death in the first 30 days P-value for comparison
hs-cTnT,Roche Diagnostics 0.85 (0.78–0.91) 19.4 88.9 72.4 99.7 5.0 0.667 0.051 0.033
hs-cTnI, Beckman-Coulter (BC) 0.83 (0.74–0.92) 20.5 88.9 76.4 99.8 5.8 — 0.146 0.132
hs-cTnI, Siemens (S) 0.75 (0.63–0.87) 21.6 72.2 73.7 99.4 4.3 0.146 — 0.798
cTnT, Roche, 4th generation (R4) 0.76 (0.64–0.89) 13.0 61.1 82.9 99.2 5.5 0.132 0.798 —
Death in the first 730 days P-value for comparison
hs-cTnT, Roche Diagnostics 0.78 (0.73–0.83) 19.4 70.7 74.8 97.0 18.2 0.001 ,0.001 ,0.001
hs-cTnI, Beckman-Coulter (BC) 0.71 (0.65–0.77) 9.9 68.3 65.6 96.3 13.6 — 0.655 0.272
hs-cTnI, Siemens (S) 0.70 (0.64–0.76) 14.6 62.2 68.9 95.8 13.7 0.655 — 0.391
cTnT, Roche, 4th generation (R4) 0.67 (0.61–0.74) 28.0 43.9 88.2 95.2 22.8 0.272 0.391 —
MI in the first 730 days P-value for comparison
hs-cTnT, Roche Diagnostics 0.64 (0.57–0.71) 11.2 71.2 58.4 97.6 7.7 0.920 0.708 0.127
hs-cTnI, Beckman-Coulter 0.64 (0.57–0.71) 5.5 80.8 47.8 98.1 7.0 — 0.760 0.083
hs-cTnI, Siemens 0.63 (0.56–0.70) 6.3 73.1 53.1 97.6 7.1 0.760 — 0.155
cTnT, Roche, 4th generation (R4) 0.58 (0.50–0.66) 9.0 75.0 37.0 96.8 5.5 0.083 0.155 —
Optimal cut-off values are displayed as nanogram per litre.
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Figure 3 (A and B) Area under the receivers operating characteristic curve displaying prognostic accuracy of high-sensitivity cardiac troponin
assays for (A) early (30 days) and (B) long-term (730 days) all-cause mortality in comparison with cTnT4 (Roche Diagnostics). (C) Kaplan–Meier
curves displaying cumulative survival during the follow-up in all acute chest pain patients stratified by presentation values of high-sensitivity
cardiac troponin above (+) and below (2) the respective 99th percentile. (D and E) Area under the receivers operating characteristic curve dis-
playing prognostic accuracy for long-term (730 days) all-cause mortality of high-sensitivity cardiac troponin assays for patients without (D) and with
(E) acute myocardial infarction at presentation in comparison with cTnT4 (Roche Diagnostics); the area under the receivers operating characteristic
curve of high-sensitivity cardiac Troponin T (Roche Diagnostics) was significantly higher than for both hs-cTnI assays in both patients with and
without acute myocardial infarction at presentation; the area under the receivers operating characteristic curve for both hs-cTnI assays in patients
with acute myocardial infarction did not reach statistical significance. Using either of the two hs-cTnI assays for the adjudication of acute myocardial
infarction did not change the above results significantly.
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with impairedrenal function (,60 mL/min/1.73 m2 glomerularfiltra-
tion rate) the prognostic accuracy of hs-cTnT (AUC: 0.69; 95% CI:
0.59–0.80) outperformed only hs-cTnI (Siemens). The prognostic
accuracy of conventional cTnT did not differ significantly in all
three subgroups in comparison with all hs-cTn assays (Table 3).
Discussion
In this prospective, observational, international, multicentre trial of
1117 unselected patients presenting with acute chest pain to the
ED, we scrutinized the prognostic value of presentation values and
serial measurements of three novel hs-cTn assays and compared
them with a conventional cTn assay. We report five major findings.
First, hs-cTnT at presentation outperformed both hs-cTnI assays
and conventional cTnTregarding the accuracy to predict 2-year mor-
tality. This finding extends previous analyses that found similar high
diagnostic accuracy for the hs-cTn assays.3,8,9 High-sensitivity
cardiac Troponin T outperformed hs-cTnI in its prognostic accuracy
both in all patients and in important subgroups such as patients with
AMI at presentation, pre-existing coronary artery disease, impaired
renal function, or patients older than 70 years. Optimal prognostic
cut-off values in these subgroups were only slightly higher than
derived from all patients. In patients with AMI at presentation only
hs-cTnT and cTnT yielded statistical significance. Secondly, novel
hs-cTn assays moderately predict mortality in patients with pre-
existing CAD, impaired renal function, and in patients older than
70 years. Thirdly, unlike in the diagnosis of AMI, neither serial mea-
surements of hs-cTn nor changes in the first 6 h provided important
additional information alone or in combination with presentation
values of hs-cTn. To the bestof our knowledge, this is the first analysis
to clearly show that—in contrast to diagnostic considera-
tions5,6,17– 21—for prognostic purposes serial measurements, abso-
lute, or relative changes of hs-cTn do not provide relevant added
value regarding risk stratification of acute chest pain patients. This
novel finding seems at least partly explained by the fact that most
patients with acute chest pain show little change in their hs-cTn con-
centration. In addition, those who do show a change are predomin-
ately those with AMI, who already have the highest concentrations
at presentation. It is important for clinicians to know that a patient’s
riskof death can reliably be estimated already with the hs-cTn value at
presentation. Fourthly, the prognostic benefit of the novel hs-cTn
assays was pronounced in acute chest pain patients without AMI
(Figure 3D), a group of patients whose troponin concentrations
often cannot be detected and quantified by conventional cTn
assays. This clinically highly relevant large group of patients can
now be better risk-stratified with hs-cTn assays. It is important to em-
phasize that in acute chest pain patients with AMI the prognostic ac-
curacy of hs-cTn assays was only moderate (Figure 3E) and other
biomarkers22,23 might be better (additional) prognosticators of mor-
tality in this patient group. Fifthly, the accuracyof the hs-cTnI assays to
predict 2-year mortality did neither differ significantly between each
other nor in comparison with conventional cTnT.
The reasoning behind the varying prognostic accuracy of the three
hs-cTn assays studied remains speculative: the range of hs-cTn values
Figure 4 Serial median high-sensitivity cardiac Troponin T
(Roche diagnostics) values in patients surviving and dying within
730 days. All values are displayed as median value (with inter-
quartile range) in nanogram per litre.
Figure 5 (A) Area under the receivers operating characteristic curve displaying prognostic accuracy of high-sensitivity cardiac Troponin T and its
early changes within the first 6 h for long-term (730 days) all-cause mortality; (B) mortality rates at 730 days for patients subdivided in six groups
according to presentation values of high-sensitivity cardiac Troponin T.
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Table 3 Prognostic performance of cardiac troponin assays during 2-year follow-up for subgroups
Death in the first 730 days AUC (95% CI) Optimal cut-off Sensitivity (%) Specificity (%) NPV (%) PPV (%) hs-cTnI (BC) hs-cTnI (S) c-TnT (R4)
Pre-existing CAD (n ¼ 402) P-value for comparison
hs-cTnT, Roche Diagnostics (RD) 0.74 (0.67–0.81) 25.6 64.9 77.1 93.0 31.9 0.037 0.001 0.142
hs-cTnI, Beckman-Coulter (BC) 0.69 (0.61–0.76) 11.2 70.2 62.6 92.7 23.7 — 0.062 0.936
hs-cTnI, Siemens (S) 0.64 (0.56–0.72) 21.2 54.4 72.2 90.5 24.4 0.062 — 0.175
cTnT, Roche, 4th generation (R4) 0.69 (0.61–0.77) 13.0 50.9 84.0 91.2 34.5 0.936 0.175 —
Impaired renal functiona (n ¼ 160) P-value for comparison
hs-cTnT, Roche Diagnostics (RD) 0.69 (0.59–0.80) 29.3 73.5 62.7 89.8 34.7 0.104 0.002 0.363
hs-cTnI, Beckman-Coulter (BC) 0.63 (0.52–0.74) 15.4 67.6 57.1 86.7 29.9 — 0.241 0.509
hs-cTnI, Siemens (S) 0.58 (0.46–0.70) 379.8 35.3 88.9 83.6 46.2 0.241 — 0.075
cTnT, Roche, 4th generation (R4) 0.66 (0.55–0.77) 106.0 41.2 88.9 84.8 50.0 0.509 0.075 —
Older than 70 years (n ¼ 406) P-value for comparison
hs-cTnT, Roche Diagnostics (RD) 0.68 (0.61–0.75) 23.1 68.2 63.8 91.2 26.8 0.027 0.008 0.118
hs-cTnI, Beckman-Coulter (BC) 0.61 (0.53–0.69) 19.8 54.5 67.9 88.5 24.8 — 0.927 0.545
hs-cTnI, Siemens (S) 0.61 (0.53–0.69) 29.5 56.1 68.2 88.9 25.5 0.927 — 0.518
cTnT, Roche, 4th generation (R4) 0.63 (0.55–0.71) 29.0 45.5 82.1 88.6 33.0 0.548 0.518 —
Optimal cut-off values are displayed as nanogram per litre. CAD, coronary artery disease.
aAll patients with a renal function ,60 mL/min/1.73 m2.
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in general and the overlap between survivors and non-survivors was
highest for the hs-cTnI (Siemens) assay, thus resulting in a lower dis-
criminatory power. Besides, hs-cTn assays measure tiny amounts of
protein: It is currently unknown whether the incidence of disturbing
phenomena such as fibrin interference or interference due to anti-
bodies varies significantly among novel hs-cTn assays.24 Ungerer
et al. 25 scrutinized four similar contemporary cTnT and cTnI assays
and concluded that the difference in cTnT and cTnI might in parts
be explainedby the fact that cTnTandcTnImeasuredifferentmoieties,
albeit that they are supposedly released in equimolar amounts via the
samepathological process. Furthermore, it is knownthathaemolysisof
even modest extent reduces cTnT and increases cTnI with some
assays.26Further studiesneed tore-evaluate thepossible impactofbio-
logical variability, assay interference such as from nonspecific antibody
binding in recently introduced hs-cTn assays and detect potential
further confounding factors influencing their prognostic accuracy.
Bonaca et al.27 showed that even small increases above the 99th
percentile of a sensitive cTn assay were associated with a significantly
higher risk of death in both short-term (30 days) and long-term (12
months) perspective and proposed the use of the 99th percentile
also for prognostic analyses. In this study, we have been able to dem-
onstrate that mortality differs considerably even among patients with
values below the 99th percentile. Detectable hs-cTn concentrations
in the ‘normal range’ represent subclinical cardiomyocyte injury and
thus may have important clinical implications.28– 30 A dichotomous
outcome stratification seems to be hardly possible with any of the
four troponin assays studied. As illustrated in Figure 5B any measur-
able amount of hs-cTnT seems to be associated with a higher risk
of mortality, even at concentrations below the 99th percentile.
Owing to the higher accuracy of hs-cTn assays at the 99th percentile
in comparison with conventional assays, we believe that hs-cTn yields
incremental prognostic benefit over the conventional cTnT assay. In
particular, the large group of acute chest pain patients without AMI
(and mainly low troponin concentrations) seems to benefit from
the higher sensitivity of novel troponin assays and improved selection
of patients at risk (Table 4; Figure 3D and E).
All new hs-cTn assays permit a quantification of cTn concentra-
tions in significant numbersofpatients without coronaryobstruction,
such as patients with heart failure, hypertensive crisis, patients with
subclinical heart disease, and even in apparently healthy subjects.
Our data as well as findings in other cohorts suggest that levels of
hs-cTn should be considered quantitative markers of cardiomyocyte
damage. The higher the hs-cTn level, the more extensive is the cardi-
omyocyte damage. The association between hs-cTn ¼ cardiomyo-
cyte damage and mortality seems to be linear. When comparing
hs-cTnT with the fourth generation cTnT, the ROC curves for
720-day mortality are superimposable for the measureable range
of the fourth generation cTnT. This indicates that both assays
provide identical sensitivity for any given specificity. In addition to
these values that provide a rather high specificity (1-specificity ¼
0,2; therefore specificity ¼ about 80%), hs-cTn assays provide mea-
surements in the undetectable range with the fourth generation assay
that indicate that those patients labelled undetectablewith the fourth
generation represent a mixed group of patients: some with actually
also very low levels of hs-cTn and therefore a very low risk of
dying, but also some patients detected to have mildly elevated
levels of hs-cTn indicating a risk of mortality that is much higher
when compared with those with really normal hs-cTn levels.
The reasoning behind the good performance of hs-cTnT in
patients with cardiac, non-coronary artery disease, and patients
with unknown cause of chest pain remains speculative: Yet, it
seems that any quantifiable amount of cardiomyocyte damage and
therefore cTn release seems to be correlated with a worse prognosis
(Figure 5B). Owing to the fact that the hs-cTnT assay is highly precise
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Table 4 Area under the receivers operating
characteristic curve for presentation values of four
cardiac troponin assays for the prediction of 730-day
mortality
AUC 95% CI P-value
Patients with AMI (40/215 non-survivors)
hs-cTnT (Roche Diagnostics) 0.64 (0.55–0.73) 0.006
hs-cTnI (Beckman-Coulter) 0.57 (0.46–0.67) 0.189
hs-cTnI (Siemens) 0.56 (0.45–0.66) 0.265
cTnT (Roche Diagnostics) 0.64 (0.55–0.73) 0.006
Patients with STEMI (10/45 non-survivors)
hs-cTnT (Roche Diagnostics) 0.64 (0.46–0.83) 0.172
hs-cTnI (Beckman-Coulter) 0.57 (0.35–0.79) 0.495
hs-cTnI (Siemens) 0.59 (0.38–0.80) 0.397
cTnT (Roche Diagnostics) 0.61 (0.42–0.81) 0.281
Patients with NSTEMI (30/170 non-survivors)
hs-cTnT (Roche Diagnostics) 0.63 (0.53–0.74) 0.023
hs-cTnI (Beckman-Coulter) 0.56 (0.45–0.68) 0.288
hs-cTnI (Siemens) 0.54 (0.42–0.66) 0.510
cTnT (Roche Diagnostics) 0.64 (0.54–0.74) 0.015
Patients with Unstable Angina (7/126 non-survivors)
hs-cTnT (Roche Diagnostics) 0.66 (0.40–0.91) 0.168
hs-cTnI (Beckman-Coulter) 0.61 (0.42–0.80) 0.335
hs-cTnI (Siemens) 0.53 (0.37–0.70) 0.766
cTnT (Roche Diagnostics) 0.66 (0.46–0.87) 0.147
Patients with cardiac, non-coronary artery disease (10/156
non-survivors)
hs-cTnT (Roche Diagnostics) 0.8 (0.71–0.89) 0.001
hs-cTnI (Beckman-Coulter) 0.54 (0.41–0.68) 0.649
hs-cTnI (Siemens) 0.66 (0.55–0.78) 0.086
cTnT (Roche Diagnostics) 0.56 (0.34–0.79) 0.517
Patients with non-cardiac chest pain (20/517 non-survivors)
hs-cTnT (Roche Diagnostics) 0.74 (0.64–0.83) ,0.001
hs-cTnI (Beckman-Coulter) 0.63 (0.51–0.75) 0.049
hs-cTnI (Siemens) 0.61 (0.49–0.73) 0.095
cTnT (Roche Diagnostics) 0.47 (0.34–0.60) 0.636
Patients with unknown cause of chest pain (5/103 non-survivors)
hs-cTnT (Roche Diagnostics) 0.79 (0.61–0.97) 0.032
hs-cTnI (Beckman-Coulter) 0.84 (0.73–0.96) 0.01
hs-cTnI (Siemens) 0.69 (0.38–0.99) 0.16
cTnT (Roche Diagnostics) 0.56 (0.29–0.84) 0.64
All P-values refer to the respective ROC curve itself.
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around the99th percentile (,10% coefficientof variation) and is able
to quantify troponin in the majority of healthy individuals, especially
patients without AMI (and low concentrations of troponin) seem to
benefit from the increased prognostic accuracy of hs-cTnT
(Figure 3C). Nevertheless, the prognostic value in these subgroups
needs to be confirmed in further prospective studies, not least
because the number of events (patients dying) in these subgroups
was relatively small in this analysis.
The prognostic accuracy as to future myocardial infarction in the
first 730 days did not differ significantly between the four cTn
assays studied and was only modest for all four assays. Nevertheless,
high NPVs could be reached by using optimal cut-off values slightly
below the 99th percentile of the respective assay (Table 2).
There was an intriguing difference in correlation between hs-cTn
assays in patients with and without AMI at presentation. Lippi et al. 31
in a small study of 47 patients reached similar conclusions as in this
study: assays of hs-cTnT and hs-cTnI display much higher values for
correlation inpatientswith thanwithoutAMI.Thenear-perfectcorrel-
ationofhs-cTnTandcTnT inpatientswithAMI incontrast toa lowcor-
relation of the two assays in all patients (and not significant correlation
in patients without AMI) might be explainable by the fact that the same
protein has been measured (with different assays) and the low sensitiv-
ity of cTnT leading to non-detectable levels of cTnT in most patients
without AMI. The near-perfect correlation of the two cTnT assays in
patients with AMI has also been shown by Lindahl et al.32 in a large
study of patients with acute coronary syndrome. But, the fact that
the correlation between the two cTnT assays in patients with AMI
was much higher than between hs-cTnI assays and between hs-cTnT
and the two hs-cTnI assays is more surprising and suggests a higher
prognostic validity of hs-cTnT than hs-cTnI. This is also expressed by
the AUC analyses: cTnT—although much less sensitive than
hs-cTnI—was not inferior as to the prognostic accuracy than hs-cTnI
assays; inpatientswithAMI itevenoutperformedtheprognosticaccur-
acyofhs-cTnIassays.Basedonourdata, althoughcTnIandcTnTreflect
thesamepathological process, theydonot seem tobe interchangeable
with each other as to their prognostic accuracy. Furthermore, correl-
ation analyses of cTn after mixing patients with and without AMI
might be misleading.
Limitations
First, as a prospective observational study,wecannot quantify exactly
the clinical benefit associated with improved risk stratification. Sec-
ondly, we cannot comment on prognostic accuracy among patients
with terminal kidney failure requiring dialysis, since such patients
were excluded from our study. Thirdly, due to the size of the study
and limited number of events that occurred during the follow-up
we cannot fully exclude a minor additional prognostic benefit of
early changes of hs-cTn. Fourthly, patients with STEMI [whose diag-
nosis is mainly based on the ECG, clinical presentation and not on
(serial) troponin measurements] are underrepresented in this ana-
lysis since their diagnosis required prompt transfer to the catheter la-
boratory, often before a 1-h value of hs-cTn could be obtained.
Fifthly, we cannot exclude the probability that cTn measurements
andchanges after the 6-hperiodwouldhave improved the prognostic
accuracy since no such study samples were taken. Sixthly, patients in
cardiogenic shock might be underrepresented in this study, since
their inclusion is hindered by proper informed consent. Seventhly,
due to inter-individual difficulties in taking blood samples and
varying patients’ willingness to accept repetitive blood withdrawals
not all serial measurements have been able to be determined in all
patients. Therefore, the statistical power of our data set may have
been too small to detect a small prognostic benefit of serial measure-
ments.
Conclusion
High-sensitivity cardiac Troponin T predicts mortality more accur-
ately than hs-cTnI assays in patients with suspected AMI. Unlike in
the diagnosis of AMI, serial measurements and changes of hs-cTn
do not seem to further improve the prognostic accuracy of presen-
tation values of hs-cTn.
Supplementary material
Supplementary material is available at European Heart Journal online.
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